PCSK9 Forum
Click here to forward this email to a colleague
Facebook Twitter RSS YouTube linkedin
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact

ACC.19 – What made the news?

Focus on lipoprotein(a) and beyond

Burgeoning evidence supports a causal role for elevated lipoprotein(a) levels in cardiovascular disease. Now, new data from ODYSSEY OUTCOMES show that elevated lipoprotein(a) contributed to the clinical benefit with alirocumab, independent of LDL cholesterol lowering in very high-risk patients with a recent acute coronary syndrome. These findings align with results from FOURIER which showed that patients with established cardiovascular disease with higher baseline lipoprotein(a) levels obtained greater clinical benefit from evolocumab treatment.

Read the report here »


Other picks from the PCSK9 Forum experts include:

View the reports from ACC.19 here »


Like us on Facebook
For the latest updates, PCSK9 news and analysis.
Follow us on Twitter
Hot topics, news and conference reports.
YouTube Channel
For videos, interviews and webcasts from leading experts.
Download Now: New Slide Deck Programme

First two decks focusing on the main results from FOURIER and ODYSSEY OUTCOMES

DOWNLOAD THEM NOW »

Register now at www.pcsk9forum.org to access our new slide deck programme.
Questions & Answers

Why are new treatments needed?


Read the full answer and other questions on the PCSK9 Forum »
Educational Partners
and Supporters
Amgen The Medicines Company Sanofi
Copyright PCSK9 Forum 2019. Please click here to unsubscribe from future mailings.